Tocilizumab improves the efficacy of anti-PD-1 in a patient with advanced gastroesophageal junction cancer: a case report

Targeting IL-6 holds promise for the management of cancer-associated inflammation and improvement of therapeutic outcomes.

Authors

Institutions

Publication Details

Journal
Frontiers in Oncology
Published
2025-04-04
DOI
https://doi.org/10.3389/fonc.2025.1530387
Primary Topic
Cancer Immunotherapy and Biomarkers
Type
article
Field-Weighted Citation Impact
0.00
Controls
|||
ALL TIME
JAN
FEB
MAR
APR
MAY
JUN
JUL
AUG
SEP
OCT
article

Tocilizumab improves the efficacy of anti-PD-1 in a patient with advanced gastroesophageal junction cancer: a case report

Yushi Cai, Yun Dai, Xuan Jin
Frontiers in Oncology
Cancer Immunotherapy and Biomarkers
article

Tocilizumab improves the efficacy of anti-PD-1 in a patient with advanced gastroesophageal junction cancer: a case report

Yushi Cai, Yun Dai, Xuan Jin
article en

Abstract

Targeting IL-6 holds promise for the management of cancer-associated inflammation and improvement of therapeutic outcomes.

Frontiers in OncologyVol. 15
Peking University (CN), Peking University First Hospital (CN)
Good health and well-being
Openalex Percentile: Top 90%
Cancer Immunotherapy and Biomarkers
DOIOpen Access PDFOpenAlex
AI Navigator

Ask Laika to Summarize, Analyze, and Connect papers live on the map.

Summarize Papers & Methodologies

Extract key findings, datasets, and comparative methods across publications.

Benchmark Rankings & Visual Analytics

Rank top research institutions, authors, funders, topics, and journals by Field-Weighted Citation Impact (FWCI) and paper volume with instant charts.

Connect Distant Disciplines

Bridge topological clusters on the map to find hidden collaborative intersections.

Tocilizumab improves the efficacy of anti-PD-1 in a patient with advanced gastroesophageal junction cancer: a case report — Yushi Cai, Yun Dai, et al. · Frontiers in Oncology (2025) | TGRS Research Map | TGRS